Literature DB >> 17483702

Leukemia in Cardio-facio-cutaneous (CFC) syndrome: a patient with a germline mutation in BRAF proto-oncogene.

Yoshio Makita1, Yoko Narumi, Makoto Yoshida, Tetsuya Niihori, Shigeo Kure, Kenji Fujieda, Yoichi Matsubara, Yoko Aoki.   

Abstract

Cardio-facio-cutaneous (CFC) syndrome is a multiple congenital anomaly/mental retardation syndrome characterized by a distinctive facial appearance, ectodermal abnormalities, and heart defects. Clinically, it overlaps with both Noonan syndrome and Costello syndrome, which are caused by mutations in 2 genes that encode molecules of the RAS/MAPK (mitogen activated protein kinase) pathway (PTPN11 and HRAS, respectively). Recently, mutations in KRAS, BRAF, and MEK1/2 have been identified in patients with CFC syndrome. Somatic mutations in KRAS and BRAF have been identified in various tumors. In contrast, the association with malignancy has not been noticed in CFC syndrome. Here we report a 9-year-old boy diagnosed with CFC syndrome and acute lymphoblastic leukemia. Sequencing analysis of the entire coding region of KRAS and BRAF showed a de novo germline BRAF E501G (1502A-->G) mutation. Molecular diagnosis and careful observations should be considered in children with CFC syndrome because they have germline mutations in proto-oncogenes and might develop malignancy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17483702     DOI: 10.1097/MPH.0b013e3180547136

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  13 in total

Review 1.  Ras and Rap signaling in synaptic plasticity and mental disorders.

Authors:  Ruth L Stornetta; J Julius Zhu
Journal:  Neuroscientist       Date:  2010-04-29       Impact factor: 7.519

2.  Cardio-facio-cutaneous syndrome: does genotype predict phenotype?

Authors:  Judith E Allanson; Göran Annerén; Yoki Aoki; Christine M Armour; Marie-Louise Bondeson; Helene Cave; Karen W Gripp; Bronwyn Kerr; Anna-Maja Nystrom; Katia Sol-Church; Alain Verloes; Martin Zenker
Journal:  Am J Med Genet C Semin Med Genet       Date:  2011-04-14       Impact factor: 3.908

3.  Molecular and functional analysis of a novel MEK2 mutation in cardio-facio-cutaneous syndrome: transmission through four generations.

Authors:  Katherine A Rauen; William E Tidyman; Anne L Estep; Srirangan Sampath; Henry M Peltier; Sherri J Bale; Yves Lacassie
Journal:  Am J Med Genet A       Date:  2010-04       Impact factor: 2.802

Review 4.  Cardio-facio-cutaneous syndrome: clinical features, diagnosis, and management guidelines.

Authors:  Mary Ella M Pierpont; Pilar L Magoulas; Saleh Adi; Maria Ines Kavamura; Giovanni Neri; Jacqueline Noonan; Elizabeth I Pierpont; Kent Reinker; Amy E Roberts; Suma Shankar; Joseph Sullivan; Melinda Wolford; Brenda Conger; Molly Santa Cruz; Katherine A Rauen
Journal:  Pediatrics       Date:  2014-09-01       Impact factor: 7.124

Review 5.  Ras/MAPK syndromes and childhood hemato-oncological diseases.

Authors:  Yoko Aoki; Yoichi Matsubara
Journal:  Int J Hematol       Date:  2012-12-19       Impact factor: 2.490

6.  Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum.

Authors:  Anna Sarkozy; Claudio Carta; Sonia Moretti; Giuseppe Zampino; Maria C Digilio; Francesca Pantaleoni; Anna Paola Scioletti; Giorgia Esposito; Viviana Cordeddu; Francesca Lepri; Valentina Petrangeli; Maria L Dentici; Grazia M S Mancini; Angelo Selicorni; Cesare Rossi; Laura Mazzanti; Bruno Marino; Giovanni B Ferrero; Margherita Cirillo Silengo; Luigi Memo; Franco Stanzial; Francesca Faravelli; Liborio Stuppia; Efisio Puxeddu; Bruce D Gelb; Bruno Dallapiccola; Marco Tartaglia
Journal:  Hum Mutat       Date:  2009-04       Impact factor: 4.878

7.  Cardio-facio-cutaneous and Noonan syndromes due to mutations in the RAS/MAPK signalling pathway: genotype-phenotype relationships and overlap with Costello syndrome.

Authors:  Caroline Nava; Nadine Hanna; Caroline Michot; Sabrina Pereira; Nathalie Pouvreau; Tetsuya Niihori; Yoko Aoki; Yoichi Matsubara; Benoit Arveiler; Didier Lacombe; Eric Pasmant; Béatrice Parfait; Clarisse Baumann; Delphine Héron; Sabine Sigaudy; Annick Toutain; Marlène Rio; Alice Goldenberg; Bruno Leheup; Alain Verloes; Hélène Cavé
Journal:  J Med Genet       Date:  2007-08-17       Impact factor: 6.318

8.  Novel MEK1 mutation identified by mutational analysis of epidermal growth factor receptor signaling pathway genes in lung adenocarcinoma.

Authors:  Jenifer L Marks; Yixuan Gong; Dhananjay Chitale; Ben Golas; Michael D McLellan; Yumi Kasai; Li Ding; Elaine R Mardis; Richard K Wilson; David Solit; Ross Levine; Kathrin Michel; Roman K Thomas; Valerie W Rusch; Marc Ladanyi; William Pao
Journal:  Cancer Res       Date:  2008-07-15       Impact factor: 12.701

9.  Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis.

Authors:  Rikhia Chakraborty; Oliver A Hampton; Xiaoyun Shen; Stephen J Simko; Albert Shih; Harshal Abhyankar; Karen Phaik Har Lim; Kyle R Covington; Lisa Trevino; Ninad Dewal; Donna M Muzny; Harshavardhan Doddapaneni; Jianhong Hu; Linghua Wang; Philip J Lupo; M John Hicks; Diana L Bonilla; Karen C Dwyer; Marie-Luise Berres; Poulikos I Poulikakos; Miriam Merad; Kenneth L McClain; David A Wheeler; Carl E Allen; D Williams Parsons
Journal:  Blood       Date:  2014-09-08       Impact factor: 22.113

10.  Spectrum of MEK1 and MEK2 gene mutations in cardio-facio-cutaneous syndrome and genotype-phenotype correlations.

Authors:  Maria Lisa Dentici; Anna Sarkozy; Francesca Pantaleoni; Claudio Carta; Francesca Lepri; Rosangela Ferese; Viviana Cordeddu; Simone Martinelli; Silvana Briuglia; Maria Cristina Digilio; Giuseppe Zampino; Marco Tartaglia; Bruno Dallapiccola
Journal:  Eur J Hum Genet       Date:  2009-01-21       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.